Related references
Note: Only part of the references are listed.Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins
Ryosuke Shirasaki et al.
CELL REPORTS (2021)
CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle-Dependent Degradation of CDK2
Kristin M. Riching et al.
SLAS DISCOVERY (2021)
Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives
Seraina Faes et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Targeting Protein Kinases Degradation by PROTACs
Fei Yu et al.
FRONTIERS IN CHEMISTRY (2021)
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
Mary Luz Uribe et al.
CANCERS (2021)
IGF2BP3 From Physiology to Cancer: Novel Discoveries, Unsolved Issues, and Future Perspectives
Caterina Mancarella et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration
Maria Krchniakova et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
Vito Amodio et al.
CANCER DISCOVERY (2020)
Proteolysis targeting chimeras (PROTACs) for epigenetics research
Anja Vogelmann et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2020)
Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
Michael J. Bond et al.
ACS CENTRAL SCIENCE (2020)
PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers
Rui Liu et al.
CELL DEATH & DISEASE (2020)
Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders
Jianping Hu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics
Jiun- Lai et al.
FRONTIERS IN ONCOLOGY (2020)
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Dhanusha A. Nalawansha et al.
CELL CHEMICAL BIOLOGY (2020)
Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
Lu Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2019)
mTOR: Role in cancer, metastasis and drug resistance
Avaniyapuram Kannan Murugan
SEMINARS IN CANCER BIOLOGY (2019)
A view on drug resistance in cancer
Neil Vasan et al.
NATURE (2019)
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Sandra Misale et al.
CLINICAL CANCER RESEARCH (2019)
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
Calla M. Olson et al.
NATURE CHEMICAL BIOLOGY (2018)
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
Chengwei Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
Philipp M. Cromm et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Daniel P. Bondeson et al.
CELL CHEMICAL BIOLOGY (2018)
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research
Jodi M. Saunus et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment
Georg E. Winter et al.
MOLECULAR CELL (2017)
Targeted protein degradation by PROTACs
Taavi K. Neklesa et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Not only P-glycoprotein: Amplification of the &ITABCB1&IT-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins
Ilaria Genovese et al.
DRUG RESISTANCE UPDATES (2017)
TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux
Ronilda D'Cunha et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2016)
ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
Aparajitha Vaidyanathan et al.
BRITISH JOURNAL OF CANCER (2016)
ABC transporters as mediators of drug resistance and contributors to cancer cell biology
Jamie I. Fletcher et al.
DRUG RESISTANCE UPDATES (2016)
Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis
Si Sun et al.
PLOS ONE (2016)
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status
F. Coscia et al.
NATURE COMMUNICATIONS (2016)
Evaluation of P-Glycoprotein Inhibitory Potential Using a Rhodamine 123 Accumulation Assay
Elodie Jouan et al.
PHARMACEUTICS (2016)
Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein
Lora D. Weidner et al.
DRUG METABOLISM AND DISPOSITION (2016)
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Michael Zengerle et al.
ACS CHEMICAL BIOLOGY (2015)
Pharmacogenomic agreement between two cancer cell line data sets
Nicolas Stransky et al.
NATURE (2015)
Tissue-based map of the human proteome
Mathias Uhlen et al.
SCIENCE (2015)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ
Juergen Cox et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
Chong Sun et al.
CELL REPORTS (2014)
Screening Compounds with a Novel High-Throughput ABCB1-Mediated Efflux Assay Identifies Drugs with Known Therapeutic Targets at Risk for Multidrug Resistance Interference
Megan R. Ansbro et al.
PLOS ONE (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance
Kevin G. Chen et al.
CLINICAL CANCER RESEARCH (2012)
Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors
Mukul Minocha et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Lapatinib for Advanced or Metastatic Breast Cancer
Frans L. Opdam et al.
ONCOLOGIST (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Gene amplification as double minutes or homogeneously staining regions in solid tumors: Origin and structure
Clelia Tiziana Storlazzi et al.
GENOME RESEARCH (2010)
The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance
K. Reed et al.
PHARMACOGENOMICS JOURNAL (2010)
Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma
Naomi Walsh et al.
BMC Urology (2009)
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2
Chun-ling Dai et al.
CANCER RESEARCH (2008)
Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells
Kerry Reed et al.
EPIGENETICS (2008)
Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs
EK Baker et al.
ONCOGENE (2005)
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma
L Pusztai et al.
CANCER (2005)
CCAAT/enhancer-binding protein β (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells
GK Chen et al.
MOLECULAR PHARMACOLOGY (2004)
Predicting drug sensitivity and resistance:: Profiling ABC transporter genes in cancer cells
G Szakács et al.
CANCER CELL (2004)
P-glycoprotein: from genomics to mechanism
SV Ambudkar et al.
ONCOGENE (2003)
Interaction of imatinib mesilate with human P-glycoprotein
A Hamada et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Share Paper
